ArticleCell death & disease2025
The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver reprogramming toward hepatocellular carcinoma following hepatitis C sustained virologic response: a narrative review.Translational gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Hippo pathway plays an important role in cell proliferation, differentiation, and cancer occurrence. Yes-associated protein 1 (YAP) is a key effector molecule of Hippo pathway. Previous studies have found abnormal YAP overexpression in many solid tumors, including hepatocellular carcinoma (HCC). Here, we attempt to explore the cancer-promoting mechanism of YAP in HCC. The target gene of Hippo-YAP pathway, Four and a half LIM domain protein 3 (FHL3), was screened by spontaneous hydrodynamic tumor model with YAP participation and two publicly HCC microarray sets. Western blot (WB) and immunohistochemical (IHC) showed high protein levels of FHL3 in tumor tissues and the expression of FHL3 was associated with poorer prognosis. The biological effect experiments showed that FHL3 significantly promoted the progression of HCC. FHL3 interacted with MYC-associated zinc finger protein (MAZ) to recruit MAZ binding to the G-quadruplexes (G4s) structure, which promoted Kirsten rat sarcoma viral oncogene homologue (KRAS) transcription and activation of its downstream signal. Down-regulating KRAS expression inhibited the promoting effect of YAP-FHL3 signaling on HCC. In addition, transactivation of FHL3 mediated by YAP was verified by luciferase reporter assay and chromatin immunoprecipitation (ChIP). FHL3 knockdown inhibited the tumor-promoting effect of YAP and significantly delayed the tumorigenesis and progression caused by YAP. Finally, clinical data validated the correlation between YAP, FHL3, and KRAS expression. In conclusion, we identified a new target of Hippo-YAP signaling, FHL3, which interacts with MAZ to promote KRAS transcription and downstream oncogenic signaling pathway activation, thereby promoting HCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.